Novo Nordisk A/S (NYSE: NVO) has disclosed the latest tranche of its ongoing share repurchase programme, reporting the acquisition of 1,239,849 B shares for a total of DKK 369,728,627 between 6 and 13 May 2026, in a filing submitted to the Securities and Exchange Commission.
The purchases were spread across six trading days at average prices ranging from DKK 290.45 on May 8 to DKK 302.39 on May 13, reflecting a consistent level of buying activity in a stock that has recovered from its multi-year lows but remains well off its historic peaks.
The tranche sits within a broader sub-programme initiated on 6 May 2026, under which Novo Nordisk is authorised to repurchase up to DKK 11.2 billion worth of B shares between that date and 1 February 2027.
That sub-programme is itself part of the company’s overarching 12-month buyback plan, which was launched on 4 February 2026 and targets a total of up to DKK 15 billion in B share repurchases over its duration.
Since the broader programme began in February, Novo Nordisk has repurchased a cumulative total of 15,999,028 B shares at an average price of DKK 260.62 per share, representing a total transaction value of DKK 4,169,728,617.
Following all transactions reported in the filing, the company now holds 33,184,329 B shares of DKK 0.10 as treasury shares, equivalent to approximately 0.7% of its total share capital of 4,465,000,000 A and B shares combined.
Novo Nordisk noted that transactions related to its employee incentive programmes resulted in a net transfer of 204,498 shares from the company over the same period, though those transfers were conducted separately and fall outside the Safe Harbour repurchase framework.
The buyback programme is being executed in compliance with Article 5 of EU Market Abuse Regulation No 596/2014 and the Commission Delegated Regulation (EU) 2016/1052, commonly referred to as the Safe Harbour Rules, which govern how listed companies can conduct share repurchases without triggering market abuse concerns.
Novo Nordisk, founded in 1923 and headquartered in Bagsvaerd, Denmark, employs approximately 67,900 people across 80 countries and markets its products in around 170 countries, with its B shares listed on Nasdaq Copenhagen and its American Depositary Receipts listed on the New York Stock Exchange under the ticker NVO.
The company’s profile has risen significantly in recent years, driven by the global commercial success of its GLP-1 portfolio including Ozempic and Wegovy, with the FDA having approved the high-dose Wegovy HD injection in March 2026 and an oral version of Wegovy having launched across the United States in January 2026.
